issues, direct intracerebroventricular injection/infusion of NTFs has been tested. In this regard, sustained-release biodegradable microspheres [2] or scaffolds loaded with NTFs implanted in the brain have been investigated. One recent approach includes implanting stem cells with scaffold that can deliver NTFs to promote differentiation of stem cells into neurons [3] . In addition, several viral vectors, including adenovirus, adeno-associated viral vectors, and lentiviruses, have been tested [4] .
The article by Herzog et al. in this issue of the journal presents data with adeno-associated viral vector, expressing one of two different NTFs: nerve growth factor (NGF) and neurturin (NRTN). The vectors were tested via direct brain injection. The data demonstrated: (1) 2-year, targeted, bioactive protein in monkeys, (2) persistent, bioactive protein throughout the life span of the rat, and (3) accurately targeted bioactive protein in aged rats, with (4) no safety issues or antibodies to the protein detected. The long-term expression of therapeutic protein in the brain is critical to combat chronic neurodegenerative diseases. The results of these studies provide empirical guidance by which to establish parameters for human dosing and collectively support the idea that gene transfer may overcome key delivery obstacles that have precluded successful translation of neurotrophic factors to the clinic. The AAV2-NGF and AAV2-NRTN vectors are now being tested in patients with Alzheimer's and Parkinson's disease, respectively, as a part of ongoing phase 2 clinical trials.
In its strategic plan, "Neuroscience in the New Millennium," the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health has pointed out that many neurological disorders will become more frequent as the US population ages. As part of its strategic plan, the NINDS hopes to invest across the full spectrum of basic, translational, and clinical research. Basic research is essential to understanding the causes and pathways involved in neurodegenerative diseases. Interventions such as deep brain stimulation (DBS), which involves the implantation of a medical device called a brain pacemaker that sends electrical impulses to specific parts of the brain, are now being used to treat a variety of disabling neurological symptoms-most commonly, the debilitating symptoms of Parkinson's disease, such as tremor, rigidity, stiffness, slowed movement, and walking problems [5] . Although DBS is helpful for some patients, there is also the potential for unintended neuropsychiatric side effects, and patients still may need to be on medication. Thus, a combined effort involving basic and translational research is needed to combat the growing epidemic of neurodegenerative diseases.
